Cidara Therapeutics Inc CDTX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if CDTX is a good fit for your portfolio.
News
-
Cidara Therapeutics Announces Presentations Highlighting Phase 1 and Phase 2a Clinical Data on CD388 at ESCMID 2024
-
CIDARA Therapeutics ALERT: Bragar Eagel & Squire, P.C. is Investigating Cidara Therapeutics, Inc. on Behalf of Cidara Therapeutics Stockholders and Encourages Investors to Contact the Firm
-
CDTX LOSS ALERT: ROSEN, A LEADING LAW FIRM, Encourages Cidara Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation – CDTX
-
Cidara Therapeutics shares surge 30% after reacquiring flu treatment
-
Cidara Therapeutics Shares Surge 42% After Re-Acquiring Flu Asset
-
Cidara Therapeutics Reacquires Global Development and Commercial Rights to CD388 and Announces Private Placement Financing of $240 Million
-
Cidara Therapeutics Announces Divestiture of Rezafungin to Mundipharma* to Focus on Advancing the Clinical Development of Cloudbreak DFC Pipeline
-
Cidara Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results
Trading Information
- Previous Close Price
- $12.68
- Day Range
- $11.75–13.20
- 52-Week Range
- $10.00–29.60
- Bid/Ask
- $11.00 / $12.51
- Market Cap
- $57.07 Mil
- Volume/Avg
- 54,051 / 60,589
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 0.86
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Cidara Therapeutics Inc is a biotechnology company. It is focused on the discovery, development, and commercialization of novel anti-infectives for the treatment and prevention of diseases. The company's REZZAYO® (rezafungin for injection) is a novel molecule in the echinocandin class of antifungals. It is developing rezafungin for the first-line treatment and prevention of serious, invasive fungal infections which are associated with high mortality rates. Its other product candidates include CD377, CD388, RSV AVC, HIV AVC, and SARS-CoV-2 AVC.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 73
- Website
- https://www.cidara.com
Comparables
Valuation
Metric
|
CDTX
|
AVIR
|
AMLX
|
---|---|---|---|
Price/Earnings (Normalized) | — | — | 1.72 |
Price/Book Value | — | 0.60 | 0.32 |
Price/Sales | 0.86 | — | 0.37 |
Price/Cash Flow | — | — | 1.83 |
Price/Earnings
CDTX
AVIR
AMLX
Financial Strength
Metric
|
CDTX
|
AVIR
|
AMLX
|
---|---|---|---|
Quick Ratio | 0.77 | 17.86 | 5.01 |
Current Ratio | 0.90 | 18.24 | 5.66 |
Interest Coverage | — | — | — |
Quick Ratio
CDTX
AVIR
AMLX
Profitability
Metric
|
CDTX
|
AVIR
|
AMLX
|
---|---|---|---|
Return on Assets (Normalized) | −31.30% | −15.46% | 18.55% |
Return on Equity (Normalized) | −371.06% | −16.16% | 21.48% |
Return on Invested Capital (Normalized) | −253.14% | −19.92% | 17.45% |
Return on Assets
CDTX
AVIR
AMLX
Biotechnology Industry Comparables
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Hnpwxnqyv | Xmcr | $545.9 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Dsdjyncd | Lhzbgy | $105.4 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Gwffcmrxq | Fvslkg | $103.7 Bil | |
MRNA
| Moderna Inc | Lblxrzrcz | Njvry | $47.9 Bil | |
ARGX
| argenx SE ADR | Nhkqynsl | Zvdk | $22.9 Bil | |
BNTX
| BioNTech SE ADR | Kpbgvss | Nlqt | $22.3 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Rpsbtlgy | Pdcqwk | $19.3 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Wycytvdyg | Jbqsrtd | $15.7 Bil | |
RPRX
| Royalty Pharma PLC Class A | Dgbggscvf | Nwthf | $12.8 Bil | |
INCY
| Incyte Corp | Wcqlcvkj | Vkvvgy | $12.1 Bil |